The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.

June 28, 2024

Vol.50 No.26

Obituary

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

In the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...

June 14, 2024

Vol.50 No.24

Clinical Roundup

Hydroxychloroquine + lapatinib may reduce breast cancer metastases

A study led by researchers from the University of Arizona Cancer Center at UArizona Health Sciences identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. The work was published in Clinical and Translational Medicine.

June 14, 2024

Vol.50 No.24

The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

YOU MAY BE INTERESTED IN

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

“Father of tamoxifen” V. Craig Jordan dies at 76

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

Hydroxychloroquine + lapatinib may reduce breast cancer metastases

Renew today!

Subscriber content

Login